Complex drugs have emerged in the COPD market, preannouncing keen competition
Following the hypertension • Diabetes treatment market, complex drugs have emerged in the COPD (Chronic Obstructive Pulmonary Disease) market, preannouncing keen competition.
As of this month 26, Novartis succeeded in receiving sales approval of 'Ultibro Breezhaler' which is a complex drug for t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
